Delving into the Latest Updates on Budesonide/Formoterol fumarate/Glycopyrronium Bromide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BGF MDI, Breztri Aerosphere, Budesonide/formoterol fumarate/glycopyrronium

+ [18]

Target

GR x mAChRs x β2-adrenergic receptor

Action

agonists, antagonists

Mechanism

GR agonists(Glucocorticoid receptor agonists), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesImmune System Diseases

Active Indication

AsthmaBronchitis, ChronicPulmonary Disease, Chronic Obstructive+ [4]

Inactive Indication-

Originator Organization

AstraZeneca PLC

Active Organization

AstraZeneca PLC

AstraZeneca Investment (China) Co. Ltd.

Pearl Therapeutics, Inc.

+ [4]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (18 Jun 2019),

Bronchitis, ChronicPulmonary Disease, Chronic ObstructivePulmonary Emphysema

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC25H34O6

InChIKeyVOVIALXJUBGFJZ-KWVAZRHASA-N

CAS Registry51333-22-3

View All Structures (3)

Preserved Ratio Impaired Spirometry (PRISm) is characterized by a normal forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio but an FEV1 below 80% of the predicted value. It has a population prevalence of approximately 10% and is associated with marked symptoms, a high risk of acute exacerbations, and increased mortality. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines PRISm as a pre-chronic obstructive pulmonary disease (COPD) state, and 20%-30% of patients with PRISm will progress to COPD. Currently, no evidence-based therapy exists for PRISm; management is mainly symptomatic relief, and there is an urgent need for evidence-based support. This single-arm clinical trial preliminarily evaluates the efficacy and safety of budesonide/glycopyrronium/formoterol inhalation aerosol in symptomatic patients with PRISm. Symptomatic smokers who meet the diagnostic criteria for PRISm and have an FEV1/FVC ratio ≥0.7 and <0.8 are enrolled and treated with budesonide/glycopyrronium/formoterol inhalation therapy for 12 weeks. The primary endpoint is the change from baseline in FEV1; secondary endpoints include symptom score (COPD Assessment Test, CAT) and quality of life (St George's Respiratory Questionnaire, SGRQ); safety is assessed by recording adverse events (e.g., cardiovascular events); and exploratory analyses examine the association between biomarkers (e.g., peripheral blood eosinophil count, serum IgE level) and treatment efficacy. The study aims to preliminarily explore the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler therapy for PRISm. Early intervention may delay the progression from PRISm to COPD, reduce the burden of chronic respiratory disease, and have important clinical translational value and public health significance.

Start Date01 Jun 2026

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

CTRI/2025/12/099667

/ Not yet recruitingPhase 4

A Phase IV study to evaluate safety and efficacy of Glycopyrronium/Formoterol/Budesonide (12.5mcg/6mcg/200mcg) triple therapy delivered through pressurized metered dose inhaler [pMDI] in patients with Chronic Obstructive Pulmonary Disease (COPD). - None

Start Date22 Jan 2026

Sponsor / Collaborator

Cipla Ltd.

CTRI/2025/12/098671

/ RecruitingPhase 4

A post-marketing phase IV, multicentre, prospective study to observe the safety and tolerability of Breztri aerosphereR containing a fixed dose combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol fumarate dihydrate 5 mcg in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

Start Date20 Jan 2026

Sponsor / Collaborator

AstraZeneca Pharma India Ltd.

100 Clinical Results associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

Login to view more data

100 Translational Medicine associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

Login to view more data

100 Patents (Medical) associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

Login to view more data

84

Literatures (Medical) associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

01 Jun 2026·RESPIRATORY MEDICINE

Outcomes of patients with COPD before and after initiation of treatment with budesonide/glycopyrrolate/formoterol fumarate: Results from the US ARCTOS study

Article

Author: Evangelista, Christopher ; Germack, Hayley D ; Feigler, Norbert ; Gozalo, Laurence ; Spy, Amanda ; Tkacz, Joseph ; Sethi, Sanjay ; Szymanski, Keith ; Hirpara, Sunny ; McMorrow, Donna

OBJECTIVE:

To assess change in COPD exacerbations, healthcare resource utilization, and costs among patients diagnosed with COPD following initiation of budesonide/glycopyrrolate/formoterol fumarate (BGF), a single inhaler triple therapy for COPD.

METHODS:

This study was a retrospective analysis of the Inovalon MORE2 Registry and 100% Medicare Fee-for-Service claims databases between 1/1/2021-3/31/2024.

INCLUSION CRITERIA:

1) prescription claim for BGF and ≥1 refill within 60 days (earliest prescription = index date), 2) ≥12 months of health plan enrollment preceding and following the index date, 3) diagnosis of COPD, 4) age ≥40 years, 5) absence of cancer and select respiratory diseases, and 6) presence of ≥1 severe or ≥2 moderate COPD exacerbations during baseline. Subgroups were established based on treatment history, baseline blood eosinophil counts and asthma comorbidity. Outcomes included COPD exacerbations, healthcare resource utilization and costs, assessed for statistically significant differences between baseline and follow-up in the overall sample and subgroups.

RESULTS:

A total of 2204 patients were included. Following initiation of BGF, mean per patient per year (PPPY) total COPD exacerbations decreased by 28.7% (3.0 ± 1.7 to 2.1 ± 2.2; p < 0.0001), while mean severe COPD exacerbations decreased by 43.9% (0.3 ± 0.6 to 0.2 ± 0.5; p < 0.0001). PPPY COPD exacerbation-related medical costs decreased by 35.7% ($4664±$9355 to $2998±$8723; p < 0.001). Pre-defined subgroups showed similar changes in outcomes.

CONCLUSIONS:

Results demonstrate that patients with COPD and a history of exacerbations had substantial reductions in exacerbations, healthcare resource utilization, and healthcare costs after initiating BGF across a variety of subgroups including patients treated with ICS/LABA during baseline and across a range of eosinophil counts.

01 Apr 2026·Lancet Respiratory Medicine

Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials

Article

Author: Bondoc, Marco ; Springer, Katarzyna ; Shah, Mihir ; Jackson, David J ; Papi, Alberto ; Obasi, Chidi ; Helman, Jesse ; Bowen, Karin ; Wise, Robert A ; Patel, Mehul ; Salter, Patricia ; Movitz, Charlotta ; Chen, Ruchong ; Lugogo, Njira ; Pandya, Hitesh ; Megally, Ayman ; Trasieva, Teodora ; Knappenberger, Katharine

BACKGROUND:

Long-acting muscarinic antagonists (LAMA) can be added to inhaled corticosteroid- (ICS)-long-acting β₂-agonist (LABA) therapy for inadequately controlled asthma. We aimed to evaluate the efficacy and safety of budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) versus budesonide-formoterol fumarate dihydrate using Aerosphere co-suspension delivery technology (BFF_A) and the current suspension formulation (Symbicort, BFF_S).

METHODS:

Two multicentre, randomised, double-blind, double-dummy, phase 3 studies (KALOS and LOGOS) recruited participants aged 12-80 years with inadequately-controlled asthma despite daily medium-dose or high-dose ICS-LABA use from across 378 sites in 20 countries (KALOS), and 324 sites in 15 countries (LOGOS). Participants were randomly assigned (1:1:1:1) to BGF 320 μg, 28·8 μg, 10 μg (BGF 28·8); BGF 320 μg, 14·4 μg, 10 μg (BGF 14·4); BFF_A 320 μg, 10 μg; or BFF_S 320 μg, 9 μg, twice a day via pressurised metered-dose inhaler for 24-52 weeks. Primary lung function endpoints were change from baseline in FEV₁ area under the curve from 0 h to 3 h (AUC_0-3) and in morning pre-dose trough FEV₁ from day 1 to week 24 (over 24 weeks; depending on regional health authority guidance). The primary pooled analysis across both studies was annualised severe exacerbations. The efficacy analysis set and safety set included all randomly assigned participants receiving any amount of study treatment but were analysed according to randomly assigned treatment and received treatment, respectively. The KALOS and LOGOS studies are registered with ClinicalTrials.gov (NCT04609878 and NCT04609904, respectively) and are complete.

FINDINGS:

Between Dec 15, 2020, and March 21, 2025 (KALOS), and between March 1, 2021, and March 20, 2025 (LOGOS), 8820 participants were recruited and 4311 received treatment (1179 received BGF 28·8, 726 received BGF 14·4, 1210 received BFF_A, and 1196 received BFF_S). In each study, the pre-specified multiplicity-adjusted primary endpoints for all regulatory comparisons were met. Least squares mean differences favoured BGF 28·8 for change from baseline in trough FEV₁ and FEV₁ AUC_0-3 across all comparisons (all p<0·05). Least squares mean differences in change from baseline in morning pre-dose trough FEV₁ and in FEV₁ AUC_0-3 over 24 weeks for BGF 28·8 versus BFF_combined were 76 mL (95% CI 57-94; p<0·0001) and 90 mL (72-108; p<0·0001), respectively. BGF 28·8 reduced severe exacerbation rates versus BFF_combined (incidence rate ratio 0·86, 95% CI 0·76-0·97; p=0·012) and versus BFF_S (0·82, 0·71-0·94; p=0·0043). Exacerbation rate ratio for BGF 28·8 versus BFF_A was 0·90 (95% CI 0·78-1·03; p=0·12). 627 (53·2%) adverse events were observed with BGF 28·8, 436 (60·0%) with BGF 14·4, 666 (55·2%) with BFF_A, and 698 (58·4%) with BFF_S. No deaths were treatment related.

INTERPRETATION:

These findings show that BGF improves lung function and reduces severe exacerbation rates in a broad population with asthma inadequately controlled despite medium-dose or high-dose ICS-LABA use. Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS-LABA before escalation.

FUNDING:

AstraZeneca.

01 Mar 2026·BIOMATERIALS

Biomimetic gingival hydrogel promotes the integrated repair of peri-implant gingiva and bone by mobilizing multiple cells

Article

Author: Zhu, Zhou ; Chen, Jingyi ; Luo, Meng ; Wan, Qianbing ; Zhu, Tong ; Zhang, Yaowen ; Liu, Yanhua ; Liu, Jiayi

During peri-implant bone augmentation surgery, insufficient gingival closure poses significant risks, including bacterial infection and loss of bone repair material, necessitating soft tissue augmentation techniques such as autologous gingival flap (AGF) grafting. However, the clinical application of AGF is limited by challenges like secondary trauma and flap inactivation. In this study, a three-dimensional printed tissue engineering biomimetic gingival flap (BGF) was designed to replace AGF by fully mimicking the composition, structure, and function of gingiva. The micropatterned gelatin methacryloyl (GelMA) modified with ε-polylysine can effectively reduce the risk of bacterial infection and reestablish the gingival barrier, while the porous GelMA can rebuild fiber networks. Promoting osteogenesis and membrane barrier functions are achieved by the dense zinc-rich GelMA. This study precisely constructed a three-layer BGF, whose surface featured a microscale honeycomb microstructure with an error of less than 1.5 %, and the middle layer was a controllable porous structure with adjustable pore sizes ranging from 10 to 70 μm. BGF exhibited broad-spectrum antibacterial activity with a bacteriostatic rate of approximately 90 %, function of promoting the regeneration of multiple tissues, and long-term membrane barrier function lasting at least 30 days. Furthermore, BGF accelerated soft tissue healing by 167.95 % and bone healing by 84.36 % in vivo through activating the paracrine effect of fibroblasts. BGF is expected to provide a more effective solution for implant patients with bone and soft tissue defects.

62

News (Medical) associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

30 Apr 2026

·www.fiercebiotech.com

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

The proceeds could rise by an additional $45 million if underwriters fully take up their option to buy an additional 2.5 million shares at the same price of $18.\n Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.The company is offering 16.6 million shares, according to an April 29 release, significantly above the 11.8 million shares the biotech had expected as recently as last week. With the share price now fixed at $18—the top end of the $16-$18 range set out last week—Avalyn is set to bring in gross proceeds of $300 million from this morning’s IPO, instead of the $180 million net proceeds it had previously been expecting.Those proceeds could rise by an additional $45 million if underwriters fully take up their option to buy an additional 2.5 million shares at the same price. Avalyn’s stock is due to begin trading on the Nasdaq April 30 under the ticker “AVLN.” Combined with the $138.4 million that Avalyn entered the year with, the extra IPO cash should make it easier for the company to fund its various pipeline plans. The company has already earmarked $150 million to advance its lead drug, AP01, through phase 2b topline data and into phase 3 development. AP01 is an inhaled formulation of pirfenidone, which is sold under many names as a pill for idiopathic pulmonary fibrosis (IPF), such as Esbriet.The company also expects $90 million will be needed to take another asset, AP02, through an ongoing phase 2 trial and into phase 3. AP02 is an inhaled version of the IPF drug nintedanib, which is marketed as Ofev and Vargatef in its oral form.Another $10 million is needed to take a third med—an inhaled combination of pirfenidone and nintedanib called AP03—into the clinic, according to the filing. To date, pairing oral therapies hasn’t been possible due to additive side effects, but Avalyn is currently running preclinical studies for the asset. The biotech currently employs 51 full-time employees, of which 32 work in R&D, according to last week’s Securities and Exchange Commission filing. The company is headed up by CEO Lyn Baranowski, whose previous roles included developing respiratory medicines at Pearl Therapeutics, which were later acquired by AstraZeneca and marketed as Breztri and Bevespi.Biotech IPO levels have fluctuated in the early months of 2026. The initial crop of offerings this year included other companies working on new formulations of approved drugs.SpyGlass Pharma, which secured a $150 million IPO in February, is developing long-acting versions of approved medicines for chronic eye conditions. Meanwhile, Veradermics, which made a splash with a $256.3 million debut on the New York Stock Exchange, is working on an oral version of the molecule behind hair loss treatment Rogaine.

IPOPhase 3Executive ChangePhase 2

30 Apr 2026

·www.fiercepharma.com

AZ's Breztri nabs FDA asthma nod, adding fuel to blockbuster launch

After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has passed another crucial milestone as it chips in on the British drugmaker’s goal to reach $80 billion in revenues by 2030. On Tuesday, the FDA approved Breztri in its second indication, clearing the triple combination therapy of budesonide, glycopyrrolate and formoterol fumarate as a maintenance treatment for asthma in adults and kids ages 12 and older. Breztri was first greenlit in the U.S. in 2020 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The new nod will unlock a substantial market for Breztri, which is one of several respiratory products driving significant sales ambitions at AstraZeneca. Last year, the drug surpassed the billion-dollar sales threshold for the first time, with revenues growing (PDF) 22% at constant currencies to nearly $1.2 billion. In turn, the drug ranks among the roster of newer AZ products enlisted in the British pharma’s campaign to hit an impressive $80 billion in sales by the end of the decade. As of January, that target still appeared “very much within reach,” the company’s CFO Aradhana Sarin said at the J.P. Morgan Healthcare Conference in San Francisco. The FDA signed off on Breztri’s new use after reviewing data from a pair of phase 3 studies, KALOS and LOGOS, which assessed the triple inhaler in a broad population of asthma patients, both with or without a recent asthma exacerbation. In the trials, Breztri charted a statistically significant and clinically meaningful improvement in lung function compared with a dual-combination control consisting of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA), AZ said. The drug also demonstrated rapid onset of action, plus significant improvement from baseline in lung function within five minutes of the first dose. There are around 27 million people living with asthma in the U.S., around half of whom struggle to control their condition on dual therapies, per AZ’s reckoning. The company added that around 10 million asthma attacks occur in the U.S. each year. As a maintenance therapy, Breztri is not indicated to relieve sudden breathing problems as a stand-in for a rescue inhaler, AZ noted. Widely available in COPD around the globe, Breztri is also in the running for asthma approvals in places like the European Union, Japan and China. Beyond Breztri, Fasenra and the Amgen-partnered Tezspire form the other major pillars of AstraZeneca’s respiratory empire. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug ApprovalBiosimilar

29 Apr 2026

·endpoints.news

AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy

AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for. Its first-quarter presentation shows it has canned a Phase 3 trial called ARTEMIS, assessing the complement inhibitor Ultomiris in acute kidney injury associated with cardiac surgery. The company said the trial showed no evidence of efficacy at an interim analysis. There were no new safety concerns, and AstraZeneca will continue to assess Ultomiris in other uses. AstraZeneca also shut down a late-stage renal cell carcinoma (RCC) trial of Imfinzi plus the MET inhibitor Orpathys, which it licensed from China’s Hutchmed. The trial missed its primary endpoint of progression-free survival versus Pfizer’s Sutent, which has been on sale for RCC for 20 years. A Phase 3 trial of Breztri in the lung disease COPD met its primary endpoint by showing improved inhaling capacity during exercise versus placebo. But AstraZeneca disclosed that the trial missed statistical significance on its second primary objective, which assessed the drug versus dual therapy with an inhaled steroid and a long-acting beta-2 agonist on measures of hyperinflation. Also, the company abandoned development of the growth hormone receptor antagonist ALXN2420, which was in a Phase 2 study for acromegaly, for strategic reasons. ALXN2420 was originally developed by the Japanese company PeptiDream and licensed to Amolyt Pharma before Amolyt’s acquisition by AstraZeneca. AstraZeneca also ended development of atuliflapon, a FLAP inhibitor, for efficacy reasons. It was in a mid-stage trial in asthma. Several other key readouts were delayed. Data from two trials of AstraZeneca’s TROP2-directed ADC Datroway in non-small cell lung cancer will now come next year, Jefferies analysts wrote in a same-day note. They added that the trial was tweaked to include biomarker measurements, and this contributed to the delayed results. Phase 3 data on the transthyretin depleter cliramitug in transthyretin amyloid cardiomyopathy are also now expected in 2027 at the earliest. AstraZeneca licensed the drug from Neurimmune in 2022. Overall, however, AstraZeneca had a good quarter. Its revenue and core operating profit increased to $15.3 billion and $5.4 billion, respectively, as sales of its kidney and heart drug Farxiga and other products including Ultomiris came in higher than Wall Street had expected.

Phase 3Phase 2AcquisitionDrug ApprovalClinical Trial Termination

100 Deals associated with Budesonide/Formoterol fumarate/Glycopyrronium Bromide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL11	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Asthma	United States	AstraZeneca AB	27 Apr 2026
Bronchitis, Chronic	Japan	AstraZeneca KK	18 Jun 2019
Pulmonary Disease, Chronic Obstructive	Japan	AstraZeneca KK	18 Jun 2019
Pulmonary Emphysema	Japan	AstraZeneca KK	18 Jun 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Moderate chronic obstructive pulmonary disease	Phase 3	United States	AstraZeneca Dunkerque Production SCS	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	United States	AstraZeneca Investment (China) Co. Ltd.	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	United States	Pearl Therapeutics, Inc.	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Japan	AstraZeneca Investment (China) Co. Ltd.	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Japan	Pearl Therapeutics, Inc.	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Japan	AstraZeneca Dunkerque Production SCS	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Canada	AstraZeneca Investment (China) Co. Ltd.	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Canada	AstraZeneca Dunkerque Production SCS	20 Aug 2015
Moderate chronic obstructive pulmonary disease	Phase 3	Canada	Pearl Therapeutics, Inc.	20 Aug 2015
Severe chronic obstructive pulmonary disease	Phase 3	United States	AstraZeneca Investment (China) Co. Ltd.	20 Aug 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04609878 \| NCT04609904 (KALOS, Pubmed \| Lancet Respir Med)	Phase 3	Asthma	8,820	Budesonide-glycopyrronium-formoterol fumarate dihydrate 320 µg, 28.8 µg, 10 µg	wguncbowqy(kbdcwygyzz) = btwdbvisue uweakjwost (bydlsaiawc )	Positive	01 Apr 2026
				Budesonide-glycopyrronium-formoterol fumarate dihydrate 320 µg, 14.4 µg, 10 µg	wguncbowqy(kbdcwygyzz) = qizzajhube uweakjwost (bydlsaiawc )
KALOS (AAAAI2026)	Phase 3	Asthma	4,311	Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) 320/36/9.6	xulaoefjir(kaqmnewtsw) = Over 24 weeks, least square mean differences (95% CIs) favored BGF 36 versus BUD/FORM (all p<0.001) for change from baseline (mL) for FEV1 AUC0-3 (KALOS: none [101 (52, 149)], 61 [68 (33, 103)]; LOGOS: none [102 (61, 143)], 61 [109 (66, 151)]). mvegwhjkax (vawhqekuvg ) View more	Positive	27 Feb 2026
				Symbicort (BUD/FORM) 320/9
NCT05573464 (CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	559	BGF MDI HFA 320/14.4/9.6 μg	mlhpssisxf = dcxsauntof zrvefkrthv (hpdovfajjp, mexkrbfeaa - oiubxebodb) View more	-	19 Sep 2025
NCT05477108 (CTgov)	Phase 1	Pulmonary Disease, Chronic Obstructive	108	BGF (Treatment A)	ywekxpsdna(pulktccgnx) = tsnaecjvof iplwmpgyqb (enddjjgrli, 61.09) View more	-	28 May 2025
				BGF (Treatment B (Replicate 1))	ywekxpsdna(pulktccgnx) = fsjnaaqghu iplwmpgyqb (enddjjgrli, 63.42) View more
MITOS EROS+CP (US) Study (ATS2025)	Not Applicable	Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome	8,837	Prompt initiation of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF)	okbkhaigye(lumewmvwev) = dxzaypduic fiaxnomuny (yttqiufnzr, 1.30 - 1.45)	Positive	16 May 2025
				Delayed initiation of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF)	okbkhaigye(lumewmvwev) = svvabcffaw fiaxnomuny (yttqiufnzr, 1.85 - 1.94)
NCT04609904 (LOGOS, Company_Website) Manual	Phase 3	Asthma	-	Breztri Aerosphere	iwjidrftqa(azffeffohl) = met all primary endpoints brsyhxdulr (iiwamyqwtd ) Met	Positive	02 May 2025
				Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg
NCT04609878 (KALOS, Company_Website) Manual	Phase 3	Asthma	-	Breztri Aerosphere	souwjkudhj(zcviltuvmr) = met all primary endpoints zxrsvcuvkw (krsmmeylql ) Met	Positive	02 May 2025
				Budesonide and formoterol fumarate
NCT05569421 (CTgov)	Phase 1	Pulmonary Disease, Chronic Obstructive	108	BAB+BGF (Treatment A)	ndsdfjklks(lazoetygtr) = rwueymtttr zxadgdbzls (ibdoxbcqnv, 46.71) View more	-	29 Apr 2025
				BAB+BGF (Treatment B (Replicate 1))	ndsdfjklks(lazoetygtr) = mkcfnlpedg zxadgdbzls (ibdoxbcqnv, 40.78) View more
NCT05472350 (Pubmed \| Transl Lung Cancer Res)	Not Applicable	Cough	-	Budesonide/glycopyrronium/formoterol fumarate co-suspension metered dose inhaler (BGF MDI)	vgchztjrwb(tooirdfgli) = Three participants in the BGF MDI group reported palpitations, with no other complications noted jhlmbelcdt (buicmwztex ) View more	Positive	01 Apr 2025
				Budesonide/glycopyrronium/formoterol fumarate co-suspension metered dose inhaler (Control group)
AURA Germany (ERS2024)	Not Applicable	Pulmonary Disease, Chronic Obstructive	1,148	Budesonide/Glycopyrrolate/Formoterol (BGF)	hcqobxkniy(iwvjlzpjsa) = tsjabbmtod roxeiroyqy (rgdgtdgfgt ) View more	Positive	07 Sep 2024